香港联交所最新资料显示，10月2日，Lazard Asset Management LLC增持国药控股(01099)23.52万股，每 股作价18.61港元，总金额约为437.71万港元。增持后最新持股数目约为1.34亿股，最新持股比例为 10.01%。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 國藥控股股份有限公司 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01099 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,341,810,740 | RMB | | 1 | RMB | | 1,341,810,740 | | 增加 / 減少 (-) | | | | | | | RMB | | | | 本月底結存 | | | 1,341,810,740 | RMB | | 1 | RMB | | 1,341,810,740 | | 2. 股份分類 | 普通股 | 股份類別 | ...

(资料图片) 格隆汇9月30日丨根据联交所最新权益披露资料显示，2025年9月24日，国药控股(01099.HK)遭 Lazard Asset Management LLC在场内以每股均价18.48港元减持54.64万股，涉资约1009.75万港元。 标签： 财经频道 财经资讯 减持后，Lazard Asset Management LLC最新持股数目为134,018,253股，持股比例由10.03%下降至 9.99%。 ...

Group 1 - Lazard Asset Management LLC reduced its stake in China National Pharmaceutical Group (国药控股) by selling 546,400 shares at an average price of HKD 18.48 per share, totaling approximately HKD 10.1 million [1] - After the sale, Lazard's total shareholding decreased to 134,018,253 shares, representing a reduction in ownership from 10.03% to 9.99% [1]

来源：新浪港股 香港联交所最新资料显示，9月24日，Lazard Asset Management LLC减持国药控股（01099）54.64万 股，每股均价18.48港元，总金额约为1009.75万港元。减持后最新持股数目约为1.34亿股，最新持股比 例为9.99%。 ...

香港联交所最新资料显示，9月24日，Lazard Asset Management LLC减持国药控股(01099)54.64万股，每 股均价18.48港元，总金额约为1009.75万港元。减持后最新持股数目约为1.34亿股，最新持股比例为 9.99%。 ...

Group 1 - Lazard Asset Management LLC reduced its holdings in China National Pharmaceutical Group (01099) by 546,400 shares at an average price of HKD 18.48 per share, totaling approximately HKD 10.0975 million [1] - After the reduction, Lazard's latest shareholding stands at approximately 134 million shares, representing a holding percentage of 9.99% [1]

Core Viewpoint - The report maintains a "Buy" rating for China National Pharmaceutical Group (国药控股) with a target price of HKD 21.3, highlighting short-term performance pressure but long-term benefits from aging trends and policy integration [1] Financial Performance - In H1 2025, the company reported revenue of CNY 286.04 billion, a decrease of 2.95% year-on-year, with a gross profit of CNY 20.35 billion, down 7.28% [1] - The overall gross margin was under pressure at 7.11%, a decline of 0.34% year-on-year, while net profit fell to CNY 5.337 billion, down 9.53% [1] - Profit attributable to equity holders was CNY 3.47 billion, a decrease of 6.43%, but effective cost control led to a reduction in selling, administrative, and financial expense ratios [1] Pharmaceutical Distribution Segment - The pharmaceutical distribution segment generated revenue of CNY 218.53 billion, down 3.52% year-on-year, with an operating profit margin of 2.58%, a decline of 0.17 percentage points [2] - The company is focusing on core hospital markets and grassroots medical needs, which has contributed to overall market share growth despite revenue decline [2] - The strategic shift to reduce low-margin revenue has improved supply chain efficiency and compliance [2] Medical Device Distribution - Revenue from the medical device distribution business was CNY 57.05 billion, down 2.46%, with an operating profit margin of 1.92%, a decrease of 0.33 percentage points [2] - The company is optimizing channel structures and has added new projects to enhance revenue, with SPD projects driving a 13% year-on-year increase in device revenue [2] Retail Pharmacy Segment - The retail pharmacy segment achieved revenue of CNY 17.16 billion, a growth of 3.6%, with an operating profit margin of 2.68%, up 1.13 percentage points [3] - As of June 30, 2025, the total number of Guoda pharmacies was 8,591, a net decrease of 978 stores, focusing on quality improvement and network optimization [3] - The net profit of the retail segment saw a significant increase of 215.8% year-on-year, driven by same-store sales growth in prescription and innovative drug support [3]

Core Viewpoint - The report maintains a "Buy" rating for China National Pharmaceutical Group (国药控股) with a target price of HKD 21.3, highlighting short-term performance pressure but long-term benefits from aging trends and policy integration [1] Financial Performance - In the first half of 2025, the company achieved revenue of CNY 286.04 billion, a decrease of 2.95% year-on-year, with a gross profit of CNY 20.35 billion, down 7.28% [1] - The overall gross margin continued to be under pressure at 7.11%, a decline of 0.34% year-on-year, while net profit was CNY 5.337 billion, down 9.53% [1] - Profit attributable to equity holders was CNY 3.47 billion, a decrease of 6.43% year-on-year, with effective cost control leading to reduced expense ratios [1] Pharmaceutical Distribution Segment - Revenue for the pharmaceutical distribution segment was CNY 218.53 billion, down 3.52% year-on-year, with an operating profit margin of 2.58%, a decline of 0.17 percentage points [2] - The company is focusing on core hospital markets and grassroots medical needs, which has contributed to overall market share growth despite revenue decline [2] - The strategic shift to reduce low-margin revenue has improved supply chain efficiency and compliance [2] Medical Device Distribution - Revenue from medical device distribution was CNY 57.05 billion, down 2.46% year-on-year, with an operating profit margin of 1.92%, a decrease of 0.33 percentage points [2] - The company is optimizing channel structures and has added new projects to enhance revenue, with SPD projects driving a 13% year-on-year increase in device revenue [2] Retail Pharmacy Segment - The retail pharmacy segment achieved revenue of CNY 17.16 billion, a growth of 3.6% year-on-year, with an operating profit margin of 2.68%, an increase of 1.13 percentage points [3] - As of June 30, 2025, the total number of Guoda pharmacies was 8,591, a net decrease of 978 stores, focusing on quality improvement and network optimization [3] - The professional pharmacy segment saw a reduction in store numbers but maintained double-digit same-store revenue growth due to supportive policies [3]

| 股份代號: | 01099 | | --- | --- | | 上市法國名稱: | 國藥控股股份有限公司 - H股 | | 日期 (日 / 月 / 年): | 29/08/2025 - 29/09/2025 | 格隆汇9月29日丨根据联交所最新权益披露资料显示，2025年9月23日，国药控股(01099.HK)遭FMR LLC在场内以每股均价18.4387港元减持131.88万股，涉 资约2431.7万港元。 减持后，FMR LLC最新持股数目为146,893,747股，持股比例由11.05%下降至10.95%。 | 表格序號 | 大股東/董事/最高行政人員名 作出披露的 買入 / 賣出或涉及的 每股的平均價 | | | | 持有權益的股份數目 佔已發行的有關事件的日 相關法 | | | --- | --- | --- | --- | --- | --- | --- | | | | 原因 | 股份數目 | | ( 請參閱上述 * 註 | | | | | | | | ler 份百分比 年) | | | | | | | | (%) | | | CS20250926E00273 | FMR LLC 1,318, ...